"&#xa0;\nWritten evidence submitted by The Academy of Medical Sciences’ (AMR0054)&#xa0;\nSummary\n \n&#xa0;&#xa0;\nIntroduction \n&#xa0;\n&#xa0;\n&#xa0;&#xa0;How has antimicrobial resistance developed in the past decade?\n&#xa0;\n&#xa0;\n&#xa0;\nWhat are the gaps in our knowledge about antimicrobial resistance? \n&#xa0;\n&#xa0;&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nWhat global coordination and action is required to fight antimicrobial resistance and is \nthe UK contributing enough towards cross-border initiatives? \n&#xa0;&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance?\n What changes might be made to further strengthen the Government’s action plan? \n&#xa0;\n&#xa0;\n&#xa0;\nPharmaceutical incentives &#xa0;\n&#xa0;\n&#xa0;Inclusion of other microbesThe growing number of effective antiviral drugs in use\n also illustrate\ns\n this point\n. In many cases their development has been catalysed by the HIV pandemic, but these are finding application in the treatment of importan\nt persistent viral pathogens in addition to HIV, such as \nh\nepatitis C. New antivirals against influenza virus are also being used at the population level. This increasing and widespread use of antiviral drugs will inevitably be accompanied by the growing em\nergence of AMR in viruses (as already seen for HIV).\n \nThus many of the proposals outlined in the strategy may be equally applied to responses to resistance in organisms besides bacteria, and these should be given appropriate weighting in the strategy’s obj\nectives. \n \nFor brevity, we have not addressed each aspect of AMR (such as\n occurrences in\n virology\n, mycology and \nparasitology) in detail individually in this response, but would be willing to provide further information to the committee \nif \nrequest\ned\n.  \n&#xa0;\nNovember 2013\n&#xa0;\n \n              \nThe Department of Health (2013). \nUK \nFive year Antimicrobial resistance Strategy 2013-2015\n.   \nhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/\nfile/244058/20130902_UK_5_year_AMR_strategy.pdf\n \n              \nTzouvelekis L\nS\n,\n \net al.\n (2012). \nCarbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions.\n Clinical Microbiology Reviews\n \n25(4), 682-707. \nhttp://www.hpa.org.uk/Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfections/1205HCAIEnglishPPSforhcaiandamu2011prelim/\n Pallares R\n,\n \net al\n. (1995). \nResistance to Penicillin and\n Cephalosporin and Mortality from Severe Pneumococcal Pneumonia in Barcelona, Spain\n. N\new\n Engl\nand\n J\nournal of\n Med\nicine\n \n333, 474-480\n.\n \nFor more information:\n \nhttp://www.hmpdacc.org/\n Morten\n \nOA\n,\n \net al. \n(2009) \nFunctional\n characterization of the antibiotic resistance reservoir in the human microflora. \nScience \n325 (5944),\n 1128-1131\n.\n \nFoxman \nB \n&amp;\n Rosenthal\n M.\n (2013)\n. Implications of the Human Microbiome Project for epidemiology\n. Am\nerican\n J\nournal of\n Epidemiol\nogy\n. \n177(3), 197-201.\n The Institute of Medicine (2000)\n.\n \nVaccines for the 21st Century: a tool for decision making\n.  \nhttp://www.nap.edu/catalog.php?record_id=5501\n  \n \n              \nFor more information:\n \nhttp://ecdc.europa.eu/en/EAAD/\n Coenen S\n,\n \net al.\n  (2013)\n.\n \nAre patient views about antibiotics related to clinician perceptions, management and outcome? A multi-country study in outpatients with acute cough. \nPLoS One\n \n8(10),&#xa0;\ne76691\n.\n \nFor more information:\n \nhttp://www.rcgp.org.uk/targetantibiotics/\n \nFor more information: \nhttp://www.stemmingthetide.org/\n \nThe World Health Organization (2002) \nImpacts of antimicrobial growth promoter termination in Denmark\n. \nhttp://www.who.int/gfn/en/Expertsreportgrowthpromoterdenmark.pdf\n \nFor mo\nre information: \nhttp://www1.imperial.ac.uk/medicine/about/institutes/cipm/centre_outputs/antimicrobialstewardship/\n \n \nFor more information: \nhttp://www.wish-qatar.org/forums/antimicrobial-resistance\n \nThe \nEuropean Union (2013)\n.\n \nProposal for a Council Regulation  for the Innovative Medicines Initiative 2 Joint  Undertaking\n. \nhttp://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0495:FIN:en:PDF\n Sing A\n,\n \net al. \n(2008)\n.\n \nMethicillin-resistant \nStaphylococcus aureus\n in a family\n and its pet cat\n.\n \nN\new\n Engl\nand\n J\nournal of \nMed\nicine\n \n358,\n1200-1201\n.\n van Duijkeren E, \net al\n. (2005)\n.\n \nTransmission of a Panton-Valentine leucocidin-positive, Methicillin-resistant \nStaphylococcus aureus\n strain between humans and a dog.\n J\nournal of\n Clin\nical\n Micr\nobiol\nogy\n&#xa0;\n43(12), 6209–6211\n.\n \nFor more information: \nhttp://www.redtractor.org.uk/home\n The US Centers for Disease Control and Prevention (2013)\n.\n \nAntibiotic resistance threats in the United States.\n \nhttp://www.cd\nc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf\n The European Centre for Disease Prevention and Control (2013). \nRisk assessment o\nn environmental use of \ntriazoles\n. \nhttp://www.ecdc.europa.eu/en/publications/publications/risk-assessment-impact-environmental-usage-of-triazoles-on-aspergillus-spp-resistance-to-m\nedical-triazoles.pdf\n The World Health Organization (2008) \nHIV Drug resistance fact sheet.\n \nhttp://www.who.int/hiv/facts/drug_resistance/en/\n"